Rib-X Pharma delays IPO after price halved

Rib-X Pharmaceuticals, a New Haven, CT-based developer of antibiotics, opted to delay a planned May 9 initial public offering after chopping the price range of its shares for the maiden stock sale in half to $6 to $7, according to Renaissance Capital. Before postponing the IPO, Rib-X was aiming to raise $65 million in the offering. The biotech, a 2011 Fierce 15 company, is only the latest drug developer to struggle in its efforts to go public. Merrimack Pharmaceuticals ($MACK), also a 2011 Fierce 15 company, delayed an IPO before completing the offering earlier this year. Report

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.